MedPath

Clinical Study of the Treovance Stent-Graft for Patients With Abdominal Aortic Aneurysms

Not Applicable
Active, not recruiting
Conditions
Abdominal Aortic Aneurysm (AAA)
Interventions
Device: Subjects who receive the Treovance stent-graft
Registration Number
NCT02009644
Lead Sponsor
Bolton Medical
Brief Summary

The purpose of this clinical trial is to assess and evaluate the safety and efficacy of the Treovance Stent-Graft with Navitel Delivery System in subjects with Abdominal Aortic Aneurysms (AAA).

Detailed Description

This is a phase II, multi-center, non-blinded, non-randomized study of treatment with the Treovance Stent-Graft in subjects with abdominal aortic aneurysms. The study will include 150 subjects treated with the Treovance Stent-Graft at a maximum of 30 investigational sites. There will be no prospective control group. Subjects diagnosed with infrarenal abdominal aortic aneurysms enrolled in the trial will be treated with the Treovance Stent-Graft with Navitel Delivery System. Pre-procedure baseline data will be gathered, as well as post-procedure assessments prior to hospital discharge and 30 days, 6 months, and 12 months post-implantation. In addition, annual follow-up visits out to 5 years will be conducted.

The primary goal of this study is to gather safety and effectiveness data on the Treovance device. A maximum of 150 endovascular subjects will be required to fulfill the U.S. Phase II requirements. The data from this study will be submitted to the FDA and used to support approval in the U.S.

There are two primary objectives, efficacy and safety of the Treovance Stent-Graft in subjects with infrarenal aortic aneurysms:

* Primary Efficacy will be evaluated by successful aneurysm treatment 12 months post-implant

* Primary Safety will be assessed by composite major adverse event (MAE) rate at 30-days

Secondary objectives involve assessment of major device-related events and major morbidity.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
150
Inclusion Criteria
  • Subject must be diagnosed with an infrarenal abdominal aortic aneurysm (AAA), with or without iliac artery involvement
  • Subject must have an infrarenal AAA that is > 4.5 cm in diameter for males, or > 4.0 cm in diameter for females, or has increased in diameter by 0.5 cm in the last 6 months
Exclusion Criteria
  • Subject has a dissection in abdominal aorta, ruptured aneurysm, or symptomatic aneurysm (as determined by treating physician)
  • Subject has had a prior AAA repair (endovascular or surgical)
  • Subject is participating in another research study, has received investigational study drug within 30 days of planned procedure, or has received an investigational device within one year of planned procedure

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
TreovanceSubjects who receive the Treovance stent-graftSubjects who receive the Treovance stent-graft
Primary Outcome Measures
NameTimeMethod
Primary Efficacy12 months

Successful aneurysm treatment which is a composite of the following: Technical success at the conclusion of the procedure; absence of aneurysm enlargement; absence of device-related complications (e.g., fracture, conversion to open surgical repair, etc.)

Primary Safety30 days

The primary safety endpoint is composite major adverse event (MAE) rate (including myocardial infarction, stroke, respiratory failure, etc.)

Secondary Outcome Measures
NameTimeMethod
Secondary Efficacy Endpoint -- Device-Related Complications30 days, 6 months, and annually

This endpoint includes the rate of complications associated with the device.

Secondary Safety Endpoint30 days, 6 months, 12 months

Secondary safety endpoints will include each individual rate for the adverse events included in the composite MAE at 30 days, 6 months, and annually.

Secondary Efficacy Endpoint-- Secondary interventions30 days, 6 months, annually

The secondary efficacy endpoint includes the rate of additional procedures performed to correct the original implant

Trial Locations

Locations (32)

Lynn Heart and Vascular Institute

🇺🇸

Boca Raton, Florida, United States

Coastal Vascular and Interventional

🇺🇸

Pensacola, Florida, United States

Avera Heart Hospital

🇺🇸

Sioux Falls, South Dakota, United States

Sanford University of South Dakota Medical Center

🇺🇸

Sioux Falls, South Dakota, United States

University of Massachusetts

🇺🇸

Worcester, Massachusetts, United States

Spectrum Health System

🇺🇸

Grand Rapids, Michigan, United States

Mount Sinai Medical Center

🇺🇸

New York, New York, United States

The Ohio State University

🇺🇸

Columbus, Ohio, United States

Arizona Heart Institute

🇺🇸

Phoenix, Arizona, United States

Mayo Clinic

🇺🇸

Rochester, Minnesota, United States

University of Alabama-Birmingham

🇺🇸

Birmingham, Alabama, United States

Danbury Hospital

🇺🇸

Danbury, Connecticut, United States

University of Chicago

🇺🇸

Chicago, Illinois, United States

Affiliated Surgeons of Rockford Memorial Hospital

🇺🇸

Rockford, Illinois, United States

Northside Hospital Heart & Vascular Institute

🇺🇸

Atlanta, Georgia, United States

University of Iowa Hospital and Clinic

🇺🇸

Iowa City, Iowa, United States

Tufts University Medical Center

🇺🇸

Boston, Massachusetts, United States

Massachusetts General Hospital

🇺🇸

Boston, Massachusetts, United States

Albany Medical Center

🇺🇸

Albany, New York, United States

Buffalo General Medical Center

🇺🇸

Buffalo, New York, United States

University of Rochester -- Strong Memorial Hospital

🇺🇸

Rochester, New York, United States

Stony Brook Medical Center

🇺🇸

Stony Brook, New York, United States

Mission Hospital

🇺🇸

Asheville, North Carolina, United States

Sanger Heart and Vascular Institute

🇺🇸

Charlotte, North Carolina, United States

University of Pittsburgh Medical Center

🇺🇸

Pittsburgh, Pennsylvania, United States

East Carolina University / Pitt County Memorial Hospital

🇺🇸

Greenville, North Carolina, United States

University of Pennsylvania

🇺🇸

Philadelphia, Pennsylvania, United States

Cleveland Clinic Foundation

🇺🇸

Cleveland, Ohio, United States

York Hospital

🇺🇸

York, Pennsylvania, United States

Temple University School of Medicine

🇺🇸

Philadelphia, Pennsylvania, United States

Sentara Vascular Specialists

🇺🇸

Norfolk, Virginia, United States

Rhode Island Hospital

🇺🇸

Providence, Rhode Island, United States

© Copyright 2025. All Rights Reserved by MedPath